Skip to content

Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)

Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02033486
Enrollment
375
Registered
2014-01-10
Start date
2014-03-31
Completion date
2021-03-31
Last updated
2019-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

diffuse optical tomography, digital breast tomosynthesis, breast cancer, solid benign lesions, cysts, malignant lesions

Brief summary

Screening for breast cancer improves early detection of aggressive cancers and has been shown to reduce breast cancer related mortality. Currently, mammography is the most effective way of detecting early stage, non palpable breast cancers. However, mammography only reveals the breast structure, and cannot say much about the breast physiological state. We propose Tomographic Optical Breast Imaging (TOBI) as an inexpensive, patient friendly technique that is non-invasive and does not use non-ionizing radiation. TOBI uses near infrared light and by measuring how such light passes through the breast, images of blood volume and hemoglobin oxygenation can be obtained. In this study, TOBI is combined with digital breast tomosynthesis (DBT, a form of 3D mammography) and our hypothesis is that the TOBI-DBT combined images can be used to diagnose breast cancer with significantly improved sensitivity and specificity compared to DBT alone.

Interventions

DEVICETOBI + DBT

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Any adult female volunteers of any race or ethnic background, between the ages of 30 to 80, either * scheduled for a clinically indicated diagnostic mammogram or percutaneous biopsy. * presenting for breast cancer treatment

Exclusion criteria

* Under 30 years old or over 80 years old * Is pregnant or thinks she may become pregnant. * Open wounds on breast * Breast implants * Any condition that impairs the ability to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Area under the curve for distinguishing benign vs malignant lesions5 yearsWe will compare optical-DBT vs DBT in terms of diagnosis specificity within the diagnostic population. We will base our analysis on total hemoglobin contrast which has been shown before by our group to be significantly different between malignant and benign lesions. By setting a threshold total hemoglobin ratio and comparing with the biopsy results, we can obtain a point on the receiver operating characteristic (ROC) for the selected parameter. By sliding the threshold over all possible values, we will render the full ROC curve. The area under the curve (AUC) will be calculated to compare with that of DBT.

Countries

United States

Contacts

Primary ContactStefan Carp, PhD
stefan.carp@mgh.harvard.edu617-643-2230
Backup ContactMansi Saksena, MBBS
msaksena@partners.org617-726-3093

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026